With Avidity and Pfizer, gene therapy enters a phase
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning, it’s Meghana today! Some gene therapy talk: Pfizer’s gene therapy for Duchenne muscular dystrophy failed in Phase 3, and gene therapy developers say Europe’s looming regulatory changes may endanger such treatments. We delve into the backstory of the $35 insulin cap, and more.
Read Original Article: With Avidity and Pfizer, gene therapy enters a phase »
